Union Korea Pharm Co., Ltd. (KOSDAQ:080720)
South Korea · Delayed Price · Currency is KRW 2,725.00
0.00 (0.00%)
At close: Oct 2, 2025
Union Korea Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Operating Revenue | 42,473 | 51,280 | 63,169 | 61,293 | 48,304 | 50,379 | Upgrade |
Other Revenue | - | - | -0 | - | - | - | Upgrade |
| 42,473 | 51,280 | 63,169 | 61,293 | 48,304 | 50,379 | Upgrade | |
Revenue Growth (YoY) | -33.87% | -18.82% | 3.06% | 26.89% | -4.12% | -1.73% | Upgrade |
Cost of Revenue | 33,369 | 37,156 | 42,388 | 37,377 | 33,154 | 31,113 | Upgrade |
Gross Profit | 9,104 | 14,124 | 20,781 | 23,917 | 15,150 | 19,267 | Upgrade |
Selling, General & Admin | 23,818 | 27,587 | 24,675 | 22,147 | 23,987 | 24,077 | Upgrade |
Research & Development | 1,004 | 1,027 | 833.33 | 922.15 | 2,451 | 988.78 | Upgrade |
Other Operating Expenses | 294.37 | 264.02 | 244.29 | 294.22 | 196.45 | 190.14 | Upgrade |
Operating Expenses | 28,642 | 32,734 | 35,463 | 22,646 | 25,764 | 30,098 | Upgrade |
Operating Income | -19,539 | -18,610 | -14,682 | 1,271 | -10,615 | -10,832 | Upgrade |
Interest Expense | -3,199 | -3,920 | -4,112 | -2,843 | -2,229 | -667.41 | Upgrade |
Interest & Investment Income | 74 | 97.74 | 105.43 | 47.61 | 46.64 | 40.06 | Upgrade |
Earnings From Equity Investments | -24.02 | -23.89 | -19.46 | -5.47 | -9.49 | - | Upgrade |
Currency Exchange Gain (Loss) | -22.09 | 89.97 | 9.98 | -55.14 | 96.43 | -108.66 | Upgrade |
Other Non Operating Income (Expenses) | 7,941 | 7,264 | 1,695 | 2,528 | -1,628 | -210.37 | Upgrade |
EBT Excluding Unusual Items | -14,769 | -15,102 | -17,004 | 943.54 | -14,338 | -11,778 | Upgrade |
Gain (Loss) on Sale of Assets | 37.49 | 0.67 | 129.04 | - | 7.54 | -306.31 | Upgrade |
Asset Writedown | - | - | - | - | -146.73 | - | Upgrade |
Other Unusual Items | -4,038 | -3,826 | 2,471 | - | - | - | Upgrade |
Pretax Income | -18,769 | -18,928 | -14,404 | 943.54 | -14,477 | -12,084 | Upgrade |
Income Tax Expense | 1,944 | 1,944 | 3,753 | 1,876 | -3,367 | -2,762 | Upgrade |
Net Income | -20,713 | -20,872 | -18,156 | -932.02 | -11,109 | -9,322 | Upgrade |
Net Income to Common | -20,713 | -20,872 | -18,156 | -932.02 | -11,109 | -9,322 | Upgrade |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 8 | 7 | Upgrade |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 8 | 7 | Upgrade |
Shares Change (YoY) | 0.07% | 0.10% | -2.14% | -5.05% | 16.95% | 12.55% | Upgrade |
EPS (Basic) | -2865.08 | -2887.58 | -2514.45 | -126.31 | -1429.59 | -1430.75 | Upgrade |
EPS (Diluted) | -2865.08 | -2888.00 | -2514.45 | -126.31 | -1430.00 | -1430.75 | Upgrade |
Free Cash Flow | -1,934 | -534.23 | -901.15 | -8,429 | -5,254 | -10,039 | Upgrade |
Free Cash Flow Per Share | -267.58 | -73.91 | -124.80 | -1142.33 | -676.09 | -1510.90 | Upgrade |
Gross Margin | 21.43% | 27.54% | 32.90% | 39.02% | 31.36% | 38.24% | Upgrade |
Operating Margin | -46.00% | -36.29% | -23.24% | 2.07% | -21.98% | -21.50% | Upgrade |
Profit Margin | -48.77% | -40.70% | -28.74% | -1.52% | -23.00% | -18.50% | Upgrade |
Free Cash Flow Margin | -4.55% | -1.04% | -1.43% | -13.75% | -10.88% | -19.93% | Upgrade |
EBITDA | -17,274 | -15,733 | -10,792 | 5,266 | -6,389 | -7,084 | Upgrade |
EBITDA Margin | -40.67% | -30.68% | -17.08% | 8.59% | -13.23% | -14.06% | Upgrade |
D&A For EBITDA | 2,265 | 2,877 | 3,890 | 3,994 | 4,226 | 3,747 | Upgrade |
EBIT | -19,539 | -18,610 | -14,682 | 1,271 | -10,615 | -10,832 | Upgrade |
EBIT Margin | -46.00% | -36.29% | -23.24% | 2.07% | -21.98% | -21.50% | Upgrade |
Effective Tax Rate | - | - | - | 198.78% | - | - | Upgrade |
Advertising Expenses | - | 302.81 | 1,984 | 865.84 | 1,090 | 1,618 | Upgrade |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.